Login to Your Account

Simcere charts new course for early stage drug discovery with VC spin-off

By Shannon Ellis
Staff Writer

Wednesday, April 16, 2014

SHANGHAI – Simcere Pharmaceutical Group made headlines in December when it announced plans to go private and delist from the NYSE. As the first Chinese biopharmaceutical company to go public in the U.S. the longtime generics maker – and growing innovative drug developer – is used to taking on pioneering projects, and looks to be at it again.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription